Recent news highlights include a reported earnings drop in August 2025 and an increase in position by investor Singer Douglas Mark in February 2023.

• Interpace Biosciences reported an earnings drop in August 2025 [N1].
• Investor Singer Douglas Mark increased his position in Interpace Diagnostics Group in February 2023 [N2].

The company’s focused molecular diagnostic tests for thyroid cancer address a significant clinical need by improving diagnosis and reducing unnecessary surgeries. Its proprietary combined testing platform offers high-performance metrics and is supported by clinical utility studies. The company’s strategy to expand awareness, improve operational efficiencies, and broaden reimbursement coverage could support growth. Its CLIA-certified and CAP-accredited laboratory and intellectual property portfolio provide a foundation for competitive differentiation. Recent profitability and positive net income in 2025 indicate operational progress.

The company faces risks from loss of reimbursement coverage, as evidenced by the discontinuation of PancraGEN following CMS reimbursement cessation. Competition from larger, better-resourced firms with broader product portfolios may pressure market share and pricing. The complexity of billing and reimbursement processes, potential changes in payer policies, and reliance on a limited number of major customers pose risks. The company’s stock delisting from Nasdaq and concentration of ownership may affect liquidity and investor perception. Technological obsolescence and the need for ongoing R&D investment also present challenges.

Interpace Biosciences’ moat derives from its proprietary molecular diagnostic tests for thyroid cancer, including the combined ThyGeNEXT and ThyraMIR v2 platform, which provides high-performance risk stratification for indeterminate thyroid nodules. The company’s CLIA-certified and CAP-accredited laboratory, issued U.S. patents, and established reimbursement contracts with major payers support its competitive position. Its focused expertise in endocrine cancer diagnostics and relationships with key customers such as LabCorp further strengthen its market presence. However, competition from larger firms with broader product lines and greater resources, such as Veracyte and Quest Diagnostics, presents ongoing challenges.

• Reimbursement Risk: Loss or reduction of reimbursement coverage by Medicare, Medicaid, or commercial payers could materially affect revenue and profitability.
• Competitive Risk: Competition from larger diagnostic companies with broader product lines and greater resources may impact market share and pricing.
• Operational Risk: Complex billing processes and potential delays in reimbursement could negatively affect cash flow and financial results.
• Technological Risk: Rapid technological and scientific changes may render existing tests obsolete or require significant investment to maintain competitiveness.
• Ownership Concentration Risk: Two private equity firms control approximately 84% of common stock, potentially influencing corporate decisions and affecting minority shareholders.

• Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services focused on cancer risk evaluation for patients with indeterminate biopsies and perceived cancer risk [S1].
• The company develops and commercializes genomic tests to personalize medicine and improve patient diagnosis and management [S1].
• Due to CMS ceasing reimbursement for the PancraGEN test in April 2025, the company discontinued PancraGEN testing after May 2, 2025 and is now concentrating on thyroid cancer molecular diagnostic tests ThyGeNEXT and ThyraMIR v2 [S1].
• Primary customers include physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics, with LabCorp as the largest customer for ThyGeNEXT and ThyraMIR in 2025 [S1].
• Revenue channels include Medicare, Medicare Advantage, Medicaid, direct client billings, and commercial payers such as Blue Cross Blue Shield, Aetna, Cigna, and United Healthcare [S1].
• The global esoteric molecular diagnostics market was valued at $29.6 billion in 2025, with a forecasted CAGR of 11.12% through 2034 according to Fortune Business Insights [S1].
• The company’s strategy focuses on organic growth and selective partnerships including licensing, acquisitions, or mergers to generate shareholder returns [S1].
• Key tactics include expanding awareness and use of ThyGeNEXT and ThyraMIR v2 through omnichannel marketing, improving operating efficiencies via automation, broadening coverage and reimbursement, expanding commercial sales staff, exploring partnerships, and leveraging bioinformatics data [S1].
• The company’s clinical services provide pathological, mutational, and epigenetic analysis of fine-needle aspiration biopsies from thyroid nodules to inform surgery or surveillance decisions [S1].
• ThyGeNEXT is a next-generation DNA and RNA sequencing oncogene and mRNA fusion panel; ThyraMIR v2 is a microRNA gene expression classifier used in combination with ThyGeNEXT to refine malignancy risk in thyroid nodules [S1].
• The estimated market for endocrine (thyroid) cancer assays is approximately $300 million annually based on patient population, biopsy numbers, and reimbursement rates [S1].
• The company’s laboratory is CLIA certified and CAP accredited, located in Pittsburgh, Pennsylvania [S1].
• Sales and marketing efforts are predominantly in the United States, using direct and indirect channels including a field-based commercial sales team of about 30 representatives and therapeutic specialists [S1].
• The company competes with larger firms such as Veracyte (Afirma test), Quest Diagnostics, and Sonic Healthcare (ThyroSeq test) in the thyroid diagnostic test market [S1].
• Research and development costs were approximately $0.6 million in 2025, focusing on supporting and improving existing products [S1].
• The company owns ten issued U.S. patents related to its products and technologies as of December 31, 2025 [S1].
• Financial snapshot as of December 31, 2025: cash and equivalents $2.505 million, current assets $9.9 million, current liabilities $5.103 million, current ratio 1.94, cash ratio 0.76 [S1].
• For fiscal year ended December 31, 2025, net income was $24.575 million, basic EPS $5.55, diluted EPS $0.89 [S1].
• Revenue for fiscal year ended December 31, 2022 was $5.678 million [S1].
• The company’s common stock was delisted from Nasdaq in February 2021 and moved to OTC markets, currently quoted on OTCID tier since August 2025 [S1].
• Two private equity firms control approximately 84% of outstanding common stock as of February 28, 2026, which may influence company decisions [S1].
• The company faces risks related to reimbursement coverage changes, competition, technological obsolescence, and the complexity of billing and collections [S1].
• Recent news includes an earnings drop reported in August 2025 and a notable increase in position by investor Singer Douglas Mark in February 2023 [N1][N2].